Oncotelic Therapeutics Inc
OTC:OTLC
Oncotelic Therapeutics Inc
Oncotelic Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Agoura Hills, California and currently employs 16 full-time employees. The firm is engaged in the development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. ArtiVeda/ArtiShield is a natural derivative from the plant Artemisia. Artemisinin derivatives are used to treat malaria. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with focus on childhood leukemia.
Oncotelic Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Agoura Hills, California and currently employs 16 full-time employees. The firm is engaged in the development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The Company’s pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. ArtiVeda/ArtiShield is a natural derivative from the plant Artemisia. Artemisinin derivatives are used to treat malaria. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with focus on childhood leukemia.
